Taiwanese President Tsai Ing-wen is expected to stop over in the U.S. on Friday on her way back from visiting diplomatic allies in the Caribbean, a move that's sure to make...China Politicsread more
Regional stability, oil prices and potential for war will all depend on what Iran does with its nuclear program in the event of the deal's termination.World Politicsread more
Libra and bitcoin are different in a lot of ways, from the technology behind them to the way they're used.Technologyread more
Stocks in major Asia Pacific markets made strong gains on Friday, as comments from a U.S. Federal Reserve official led to rising expectations the central bank could ease...Asia Marketsread more
Boeing will take a nearly $5 billion charge in the second quarter to compensate 737 Max customers as the planes remain grounded.Airlinesread more
Earlier, Williams delivered a speech at the annual meeting of the Central Bank Research Association in which he said, "It's better to take preventative measures than to wait...The Fedread more
The base version of the sports car will punch out 495 horsepower, 40 more than the seventh-generation car and enough to launch it from 0 to 60 in "less than three seconds"...Autosread more
Animation fans and Kyoto residents gathered at the site of Japan's worst mass killing in 18 years on Friday, offering flowers and prayers for the 33 people who died in an...Asia Newsread more
Trump said the USS Boxer destroyed Iran's drone in the Strait of Hormuz on Thursday in a "defensive action."Politicsread more
Microsoft beat on top and bottom lines, and guidance was just ahead of expectations, but the company's Azure growth is slowing down.Technologyread more
"We've seen Netflix stumble before, especially maybe after a price hike, but not quite like this," Jim Cramer says.Mad Money with Jim Cramerread more
Rani Therapeutics, a start-up with a new way to turn injectable drugs like insulin into pills, has raised another $39 million, bringing its total cash haul to $100 million.
The pharmaceutical sector has long searched for ways to alleviate the $289 billion annual cost of patients that neglect to take their medication. Many of these patients will avoid needle-based injections in particular, as they can be scary, expensive and/or painful.
For that reason, the so-called "oral biologics" space presents a huge opportunity for life sciences start-ups, but it also comes with significant technological hurdles.
Rani's approach involves delivering an injection straight into the intestinal wall, which the company's CEO Mir Imran describes as "pain-free."
The company has devised a robotic pill that moves through the stomach, causing the outer case to dissolve in the small intestine.
A valve releases, fusing two previously separated chemicals to form carbon dioxide. That generates the necessary force to inject a needle-like structure made of sugar into the intestinal wall. That needle will then dissolve naturally, said Imran.
The company's technology is not currently used by patients, as it is still in the pre-clinical trials phase and has not yet been tested on humans.
Imran expects that the company will bring its technology to market in "two to three" years with an initial focus on diabetes, rheumatoid arthritis and other common, chronic conditions.
The new funding brings the company's total to $100 million. Current and existing investors include GV, Alphabet's ventures arm, as well as drug makers Novartis and Astra Zeneca.